Immunity Enhancing Composition with Amide Compound
Summary
The USPTO has published a patent application (US20260083715A1) for a composition containing a novel amide-based compound derived from amino acids. The composition is designed to enhance immunity by activating macrophage phagocytosis, aiding in the removal of pathogenic bacteria.
What changed
This document is a published patent application from the USPTO detailing a novel amide-based compound derived from amino acids (such as valine, leucine, phenylalanine, proline, or pipecolic acid). The application, titled 'Immunity Enhancing Composition with Amide Compound,' describes a composition that aims to enhance immune function by activating macrophage phagocytosis, which is crucial for eliminating pathogenic bacteria.
This publication represents a new intellectual property filing and does not impose immediate regulatory obligations on entities. However, it signals potential future developments in the pharmaceutical sector related to immune-enhancing compounds. Companies involved in drug development, particularly those focusing on immunology or novel therapeutic agents, should be aware of this filing as it may influence future research, development, and patent landscapes in this area.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITION FOR ENHANCING IMMUNITY CONTAINING AMIDE-BASED COMPOUND
Application US20260083715A1 Kind: A1 Mar 26, 2026
Assignee
AMOREPACIFIC CORPORATION
Inventors
Eun Jeong CHOI, Geunhyuk JANG, Hyunjung CHOI, Hyoung June KIM, Wonseok PARK, Heungsoo BAEK, Jaewon YOU
Abstract
The present specification relates to a composition containing a novel amide-based compound derived from an amino acid structure such as valine, leucine, phenylalanine, proline, or pipecolic acid, and the composition can exhibit an immune-enhancing effect by activating the phagocytosis of macrophages, which aids in removing pathogenic bacteria as an important part of the human immune system.
CPC Classifications
A61K 31/445 A61K 31/197 A61K 31/40 A61P 37/04
Filing Date
2025-09-22
Application No.
19335570
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.